Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 171.74% from the stock's current price.

Several other equities analysts have also recently commented on DAWN. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Wedbush reaffirmed an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Needham & Company LLC increased their target price on Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. Piper Sandler reaffirmed an "overweight" rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Finally, Bank of America raised Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and increased their target price for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $35.71.

Day One Biopharmaceuticals Stock Performance

DAWN traded up $0.25 on Thursday, reaching $14.72. 4,070,943 shares of the company's stock were exchanged, compared to its average volume of 936,002. The company's 50 day moving average is $14.18 and its 200-day moving average is $14.39. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -7.55 and a beta of -1.51. Day One Biopharmaceuticals has a twelve month low of $10.90 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analysts' expectations of $15.05 million. During the same quarter in the prior year, the company earned ($0.54) EPS. Sell-side analysts forecast that Day One Biopharmaceuticals will post -1.68 EPS for the current year.

Insider Activity

In other news, CFO Charles N. York II sold 2,633 shares of the firm's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the transaction, the chief financial officer now directly owns 232,485 shares of the company's stock, valued at approximately $3,254,790. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Charles N. York II sold 2,633 shares of the firm's stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the transaction, the chief financial officer now owns 232,485 shares of the company's stock, valued at $3,254,790. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Samuel C. Blackman sold 30,000 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares of the company's stock, valued at $15,606,947.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,748 shares of company stock valued at $689,072. Company insiders own 8.40% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after buying an additional 1,002 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $113,000. Point72 DIFC Ltd acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $124,000. Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $163,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at $221,000. Institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.